Vorasidenib, an IDH-1 and IDH-2 inhibitor improved the progression free survival (27.7 months vs. 11.1 months) compared to placebo in patients with residual or recurrent grade 2 oligodendroglioma or astrocytoma in a phase III trial. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).